leadf
logo-loader
viewBiocept Inc

Biocept updates on Aegea partnership, 2Q earnings, and coronavirus test deployment

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall updates Proactive on a series of company highlights. Nall says the firm has reached an agreement with Aegea Biotechnologies Inc, a privately held life sciences company, to co-develop a polymerase chain reaction (PCR) assay to detect the coronavirus (COVID-19).

In addition, Nall spoke about the California company's recent 2Q, as well as its agreement with a California-based healthcare group to deliver coronavirus testing to nursing facilities across the US.

Quick facts: Biocept Inc

Price: 4.36 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $58.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read